â€œThere is hope in dreams, imagination, and in the courage of those who
is leading the effort to combat influenza and other
At Ansun, we are committed to developing safe and effective immuno-biologic therapies to treat the most vulnerable patients.
is currently working with to plan and implement a Phase 3 clinical trial of DAS181 for the treatment of infection in hospitalized and immunocompromised patients.
DAS181 has received both Fast Track and Breakthrough Therapy designations by the for this indication.
has observed activity of DAS181 against other important respiratory pathogens based on the same host-directed anti-viral mechanism.
